Background: Local recurrence after radiation therapy for prostate cancer is a major clinical issue. Various local treatments are available with mitigated functional and oncological outcomes. The aim of the present study was to evaluate perioperative and oncological results of salvage cryotherapy (CT) as treatment of local recurrence of prostate cancer. Methods: We retrospectively reviewed all patients treated with hemi-prostatic salvage CT for local recurrence of prostate cancer in 1 academic hospital between November 2011 and April 2019. Local recurrence was defined according to the Phoenix criteria (prostate-specific antigen [PSA] nadir + 2 ng/mL), associated with a prostatic MRI target lesion and confirmed by biopsy. Perioperative and functional complications were collected. Cox regression was conducted to assess factors associated with time to initiation of androgen deprivation therapy (ADT). Statistical analyses were conducted using R Studio. Results: A total of 29 patients were treated with an average follow-up of 37.6 months. Median age at CT was 77 years. Median PSA before CT was 5.1 ng/mL (min-max: 2.74–18). 17.2% of patients displayed a high D’Amico risk group. Median hospital stay was 1.4 days. Four patients (13.8%) experienced postoperative acute urinary retention. Nineteen patients (65.5%) experienced late functional complications (3 erectile dysfunctions, 3 stress incontinence, and 13 urinary frequency). Fourteen patients displayed recurrence after salvage treatment (48.2%). Median time to introduction of ADT was 15.1 months. ADT-free survival at 1 and 2 years was, respectively, 74% and 61%. In multivariate analysis, ISUP score 4 and PSA nadir <1 ng/mL after CT were significantly associated with time to ADT initiation. Conclusions: Salvage focal CT may delay the use of ADT in locally recurrent prostate cancer after RT and offers an alternative for eligible patients. The technique was feasible with acceptable perioperative morbidity and acceptable midterm oncological outcome.

1.
Rawla
P
.
Epidemiology of prostate cancer
.
World J Oncol
.
2019
;
10
(
2
):
63
89
. .
2.
Cornford
P
,
van den Bergh
RCN
,
Briers
E
,
Van Den Broeck
T
,
Cumberbatch
MG
,
De Santis
M
,
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer
.
Eur Urol
.
2021;79(2):263–82
.
3.
Agarwal
PK
,
Sadetsky
N
,
Konety
BR
,
Resnick
MI
,
Carroll
PR
.
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes
.
Cancer
.
2008
;
112
:
307
14
. .
4.
Kupelian
PA
,
Buchsbaum
JC
,
Patel
C
,
Elshaikh
M
,
Reddy
CA
,
Zippe
C
,
Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era
.
Int J Radiat Oncol Biol Phys
.
2002
;
52
:
704
11
. .
5.
Chen
CP
,
Weinberg
V
,
Shinohara
K
,
Roach
M
 3rd
,
Nash
M
,
Gottschalk
A
,
Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes
.
Int J Radiat Oncol Biol Phys
.
2013
;
86
:
324
9
. .
6.
Dason
S
,
Wong
NC
,
Allard
CB
,
Hoogenes
J
,
Orovan
W
,
Shayegan
B
.
High-intensity focused ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response
.
Int Braz J Urol
.
2018
;
44
:
248
57
. .
7.
Salagierski
M
,
Wojciechowska
A
,
Zając
K
,
Klatte
T
,
Thompson
RH
,
Cadeddu
JA
,
The role of ablation and minimally invasive techniques in the management of small renal masses
.
Eur Urol Oncol
.
2018
;
1
:
395
402
. .
8.
Uchio
EM
,
Aslan
M
,
Wells
CK
,
Calderone
J
,
Concato
J
.
Impact of biochemical recurrence in prostate cancer among US veterans
.
Arch Intern Med
.
2010
;
170
:
1390
5
. .
9.
Gevorgyan
A
,
Hetet
JF
,
Robert
M
,
Duchattelle-Dussaule
V
,
Corno
L
,
Boulay
I
,
Salvage cryotherapy of prostate cancer after failed external radiotherapy and brachytherapy: morbidity and mid-term oncological results
.
Prog Urol
.
2018
;
28
:
291
301
.
10.
Spiess
PE
,
Levy
DA
,
Pisters
LL
,
Mouraviev
V
,
Jones
JS
.
Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry
.
World J Urol
.
2013
;
31
:
1321
5
. .
11.
Lian
H
,
Yang
R
,
Lin
T
,
Wang
W
,
Zhang
G
,
Guo
H
.
Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy
.
Int Urol Nephrol
.
2016
;
48
:
1461
6
. .
12.
Ghafar
MA
,
Johnson
CW
,
De La Taille
A
,
Benson
MC
,
Bagiella
E
,
Fatal
M
,
Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience
.
J Urol
.
2001
;
166
:
1333
7
.
13.
Williams
AK
,
Martínez
CH
,
Lu
C
,
Ng
CK
,
Pautler
SE
,
Chin
JL
.
Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer
.
Eur Urol
.
2011
;
60
:
405
10
. .
14.
Chin
JL
,
Pautler
SE
,
Mouraviev
V
,
Touma
N
,
Moore
K
,
Downey
DB
.
Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications
.
J Urol
.
2001
;
165
:
1937
2
. .
15.
Philippou
P
,
Yap
T
,
Chinegwundoh
F
.
Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre’s experience
.
Urol Int
.
2012
;
88
:
137
44
. .
16.
Kongnyuy
M
,
Berg
CJ
,
Kosinski
KE
,
Habibian
DJ
,
Schiff
JT
,
Corcoran
AT
,
Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients
.
Int J Hyperthermia
.
2017
;
33
:
810
3
. .
17.
Li
YH
,
Elshafei
A
,
Agarwal
G
,
Ruckle
H
,
Powsang
J
,
Jones
JS
.
Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry
.
Prostate
.
2015
;
75
:
1
7
. .
18.
Nguyen
PL
,
D’Amico
AV
,
Lee
AK
,
Suh
WW
.
Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature
.
Cancer
.
2007
;
110
:
1417
28
.
19.
Murat
FJ
,
Poissonnier
L
,
Rabilloud
M
,
Belot
A
,
Bouvier
R
,
Rouviere
O
,
Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer
.
Eur Urol
.
2009
;
55
:
640
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.